Aeterna Zentaris Inc
TSX:AEZS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kyland Technology Co Ltd
SZSE:300353
|
CN |
Aeterna Zentaris Inc
Capital Expenditures
Aeterna Zentaris Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aeterna Zentaris Inc
TSX:AEZS
|
Capital Expenditures
-$24k
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$563m
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$437.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
|
Aeterna Zentaris Inc
Glance View
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 17 full-time employees. The firm's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The firm focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
What is Aeterna Zentaris Inc's Capital Expenditures?
Capital Expenditures
-24k
USD
Based on the financial report for Mar 31, 2024, Aeterna Zentaris Inc's Capital Expenditures amounts to -24k USD.
What is Aeterna Zentaris Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
11%
The average annual Capital Expenditures growth rates for Aeterna Zentaris Inc have been 64% over the past three years , and 11% over the past ten years .
